• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Pathway Therapeutics

edit

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Milestones

edit

• 
  Pathway Therapeutics added Julie Cherrington as President & CEO.
  Posted 5/25/11 at 6:50pm
• 
  Pathway Therapeutics received $7.5M in Series A funding. (5/25/11)
  Posted 5/25/11 at 6:50pm via pathwaytx.com
• 
  Pathway Therapeutics received $4.5M in Series A funding. (8/10/10)
  Posted 5/25/11 at 6:50pm via pathwaytx.com
• 
  Pathway Therapeutics received $2.4M in Series A funding. (10/9/09)
  Posted 5/25/11 at 6:50pm via pathwaytx.com
• 
  Pathway Therapeutics received $9.6M in Series A funding. (6/18/08)
  Posted 5/25/11 at 6:50pm via pathwaytx.com

Videos

Screenshots

edit

Above: Pathway Therapeutics
Uploaded: 5/26/11

Sources

1. $10million for Pathway cancer drugs (pathwaytx.com) [edit]
2. Pathway Therapeutics Completes $3Million Financing for Cancer Programs and appoints Dr Julie Cherrington as Chief Executive Officer (pathwaytx.com) [edit]
3. Pathway Therapeutics Completes $4.5 Million Financing for Novel PI3K Inhibitor Portfolio (pathwaytx.com) [edit]
4. FDA Approves Trial of Pathway Therapeutics, Inc. Cancer Drug; $7.5 Million Financing in Place to Advance Novel PI3K/mTOR Inhibitor Portfolio (pathwaytx.com) [edit]